Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
This captivating conversation analyzes how patients can perceive acromegaly symptoms and quality of life differently than their physicians. It offers an intimate look at how endocrine fellows train on pituitary disorders and their confidence in managing these conditions post-fellowship. Importantly, the discussion also identifies the gaps in acromegaly care, exploring whether these are potentially linked to gaps in physician training or other factors.
Two patients with residual pituitary tumors and their unpredictable differences.
With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed 58% of patients maintained normal IGF-1 levels with the new oral
From Risa Heidt, triathlete, ironwoman – Marshmallow Clouds – It was September 2018. In preparation for my next big cycling event, a 100-mile Century ride in New Mexico, I rode 50 miles a day for weeks
Acromegaly patients and healthcare providers worldwide can participate in this survey designed to provide information that may help improve quality of life during the COVID-19 pandemic. Much of this initiative’s success will depend on your
Dr. Manel Puig Domingo, a leading endocrinologist in Barcelona, is doing important work on facial recognition and biometrics to see if this technology is useful in recognizing the early physical changes that occur in Acromegaly.
Note: Muscle weakness affects the quality of life in people with acromegaly. Doctora Elena Valassi takes a fascinating look at what happens to muscles when exposed to excess Growth Hormone. Her work is of paramount
Podcast and Survey: Clinical features of acromegaly. In this podcast, Dr. Blevins dives into those clinical features of Acromegaly with a fascinating discussion about symptoms and signs and gives us an unfettered glimpse into the
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,
We caught up with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center and the Barrow Neuroendocrinology Clinic in Phoenix, Arizona, and Dr. Lewis Blevins Medical Director of the California Center for Pituitary Disorders at
Your insights matter. From J D Faccinetti – co-founder and chief editor – In the awareness business coming up with new, fresh, creative ideas is essential to get your message across, particularly these days when breaking
Dr. Alan Krasner, Chief Medical Officer, and Dr. Chris Cook, Medical Director, Endocrinology at Crinetics Pharmaceuticals offer an in-depth look at clinical studies. In this podcast, we cover a promising molecule – CRNOO808 – under
A few weeks ago, Dan Jeffreys, a UK based author, musician, and patient advocate sent me a message to tell me about his latest project. He told me he started AcroTales to encourage people to share their